Israel Englander’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.94M Sell
136,625
-157,070
-53% -$8.53M ﹤0.01% 2541
2026
Q1
$17.1M Sell
293,695
-130,599
-31% -$7.09M 0.01% 1681
2025
Q4
$19.6M Sell
424,294
-524,673
-55% -$23.5M 0.01% 1598
2025
Q3
$34.2M Sell
948,967
-155,872
-14% -$5.16M 0.01% 1152
2025
Q2
$35.9M Buy
1,104,839
+691,410
+167% +$22.7M 0.02% 1046
2025
Q1
$15.6M Buy
413,429
+136,851
+49% +$10.9M 0.01% 1766
2024
Q4
$22.6M Sell
276,578
-21,857
-7% -$2.17M 0.01% 1420
2024
Q3
$34.1M Buy
298,435
+94,704
+46% +$8.54M 0.02% 1098
2024
Q2
$15.4M Sell
203,731
-3,251
-2% -$221K 0.01% 1710
2024
Q1
$14.1M Sell
206,982
-484,450
-70% -$33.5M 0.01% 1856
2023
Q4
$43.4M Buy
691,432
+108,563
+19% +$5.64M 0.02% 894
2023
Q3
$29.7M Sell
582,869
-631,203
-52% -$31.1M 0.02% 1096
2023
Q2
$60.6M Sell
1,214,072
-99,570
-8% -$4.72M 0.03% 614
2023
Q1
$49.2M Buy
1,313,642
+94,151
+8% +$3.99M 0.03% 700
2022
Q4
$58.5M Buy
1,219,491
+433,169
+55% +$17M 0.03% 665
2022
Q3
$18.9M Buy
786,322
+220,206
+39% +$5.58M 0.01% 1399
2022
Q2
$12.3M Buy
566,116
+303,396
+115% +$7.02M 0.01% 1784
2022
Q1
$6.34M Sell
262,720
-23,603
-8% -$516K ﹤0.01% 2675
2021
Q4
$6.81M Buy
286,323
+5,039
+2% +$117K ﹤0.01% 2576
2021
Q3
$7.14M Sell
281,284
-34,329
-11% -$832K ﹤0.01% 2470
2021
Q2
$7.1M Sell
315,613
-37,841
-11% -$775K ﹤0.01% 2309
2021
Q1
$6.98M Sell
353,454
-72,370
-17% -$1.82M 0.01% 2196
2020
Q4
$11.3M Buy
425,824
+330,164
+345% +$12.3M 0.01% 1595
2020
Q3
$4.72K Sell
95,660
-772,658
-89% -$30.8M 0.01% 1895
2020
Q2
$27.4M Buy
+868,318
New +$27.9M 0.04% 561

Other funds holding PCVX

Israel Englander's PCVX Position: Q2 2026 in Review

Israel Englander reduced its Vaxcyte (PCVX) stake by 53% in Q2 2026, selling an estimated $8.53M and leaving 136,625 shares worth $7.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2541.

Israel Englander first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $60.6M in Q2 2023. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Israel Englander held 136,625 shares of Vaxcyte worth $7.94M as of Q2 2026.
  • Israel Englander sold 157,070 Vaxcyte shares in Q2 2026, an estimated $8.53M.
  • Vaxcyte made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2541 holding.
  • Israel Englander first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • Israel Englander's Vaxcyte position peaked at $60.6M in Q2 2023.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.